<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7362854\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Introduction The current pandemic coronavirus disease-2019 (COVID-19) is a new" exact="infectious" post="pneumonia-like illness caused by a novel virus strain, so-called"/>
  <result pre="pneumonia-like illness caused by a novel virus strain, so-called severe" exact="acute" post="respiratory syndrome coronavirus 2 or SARS-CoV-2 [1,2]. This virus"/>
  <result pre="illness caused by a novel virus strain, so-called severe acute" exact="respiratory" post="syndrome coronavirus 2 or SARS-CoV-2 [1,2]. This virus is"/>
  <result pre="caused by a novel virus strain, so-called severe acute respiratory" exact="syndrome" post="coronavirus 2 or SARS-CoV-2 [1,2]. This virus is a"/>
  <result pre="the Î²-Coronaviruses genus (family Coronaviridae) and is similar to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) [3] and Middle East respiratory"/>
  <result pre="Î²-Coronaviruses genus (family Coronaviridae) and is similar to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) [3] and Middle East respiratory syndrome"/>
  <result pre="genus (family Coronaviridae) and is similar to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) [3] and Middle East respiratory syndrome coronavirus"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) [3] and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) [4]. The common symptoms of a"/>
  <result pre="acute respiratory syndrome coronavirus (SARS-CoV) [3] and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) [4]. The common symptoms of a person"/>
  <result pre="The common symptoms of a person infected with SARS-CoV-2 include" exact="respiratory" post="symptoms, fever, dry cough, shortness of breath, and central"/>
  <result pre="include respiratory symptoms, fever, dry cough, shortness of breath, and" exact="central nervous system" post="conditions leading to multiple organ failure. In more severe"/>
  <result pre="conditions leading to multiple organ failure. In more severe cases," exact="infection" post="causes bilateral pneumonia, acute respiratory distress syndrome, kidney failure,"/>
  <result pre="to multiple organ failure. In more severe cases, infection causes" exact="bilateral" post="pneumonia, acute respiratory distress syndrome, kidney failure, and ultimately,"/>
  <result pre="organ failure. In more severe cases, infection causes bilateral pneumonia," exact="acute" post="respiratory distress syndrome, kidney failure, and ultimately, death [5,6]."/>
  <result pre="failure. In more severe cases, infection causes bilateral pneumonia, acute" exact="respiratory" post="distress syndrome, kidney failure, and ultimately, death [5,6]. Current"/>
  <result pre="severe cases, infection causes bilateral pneumonia, acute respiratory distress syndrome," exact="kidney failure," post="and ultimately, death [5,6]. Current data on COVID-19 indicate"/>
  <result pre="COVID-19 indicate that the SARS-CoV-2 mortality rate is generally far" exact="lower" post="(3â€&quot;5%) than that of SARS-CoV (9â€&quot;15%) and MERS-CoV (34â€&quot;37%),"/>
  <result pre="date (June 04, 2020), more than 11million worldwide cases of" exact="infection" post="and 525.491 deaths have been attributed to the novel"/>
  <result pre="treatment of COVID-19 are still controversial. Fortunately, after analyzing the" exact="complete" post="genome of SARS-CoV-2 from Wuhan, China [13,14], important structural"/>
  <result pre="now available on this coronavirus and its clinical features: 1.The" exact="viral" post="genome consists of more than 29,000 bases and encodes"/>
  <result pre="dipeptidyl peptidase 4 (DPP4) receptor through its spike glycoprotein [22]." exact="Viral" post="spike glycoproteins (SARS-CoV-2 virus) can also bind to the"/>
  <result pre="feature apparently gives the virus its high ability to cause" exact="pneumonia" post="[20,23]; 4.Upon entering the host cells, in the cytoplasm,"/>
  <result pre="[20,23]; 4.Upon entering the host cells, in the cytoplasm, the" exact="viral" post="genome is released as a positive sense single-stranded RNA,"/>
  <result pre="interferon regulatory factor 3 (IRF3), with the subsequent production of" exact="type I" post="interferons (IFN-Î±/Î²) and a series of pro-inflammatory cytokines including"/>
  <result pre="violent attack on the body by the immune system, initiating" exact="acute" post="respiratory distress syndrome and multiple organ failure. Based on"/>
  <result pre="attack on the body by the immune system, initiating acute" exact="respiratory" post="distress syndrome and multiple organ failure. Based on this"/>
  <result pre="the body by the immune system, initiating acute respiratory distress" exact="syndrome" post="and multiple organ failure. Based on this information and"/>
  <result pre="search. Most of the drugs examined for treatment of this" exact="disease" post="fall into the following drug classifications: antiviral with broad"/>
  <result pre="drugs selected by experts in antiviral research and clinical parasitic" exact="infections" post="were analyzed from the point of view of bioavailability"/>
  <result pre="COVID-19? Using the main potential targets and their roles in" exact="viral infection," post="many researchers have attempted to collect lists of possible"/>
  <result pre="[36], [37]]. However, due to the critical situation of coronavirus" exact="disease" post="2019, the WHO launched a megatrial to test selected"/>
  <result pre="from the use of an approved drug should be significantly" exact="lower" post="than from the disease itself. Therefore, the medicine must"/>
  <result pre="an approved drug should be significantly lower than from the" exact="disease" post="itself. Therefore, the medicine must be safe. This fact"/>
  <result pre="Gilead Sciences (Foster City, CA, USA) to combat the West" exact="African" post="Ebola virus disease epidemic in the mid-2010s. This nucleotide"/>
  <result pre="City, CA, USA) to combat the West African Ebola virus" exact="disease" post="epidemic in the mid-2010s. This nucleotide prodrug has also"/>
  <result pre="drug, approved by FDA in 2001 for the treatment of" exact="HIV infection" post="in adults [52,53]. Favipiravir (T-705, AviganÂ®) is a pyrazinecarboxamide"/>
  <result pre="approved by FDA in 2001 for the treatment of HIV" exact="infection" post="in adults [52,53]. Favipiravir (T-705, AviganÂ®) is a pyrazinecarboxamide"/>
  <result pre="a nucleoside analog, ribonucleotide T-705-4-ribofuranosyl-5â€²-monophosphate, which inhibits the activity of" exact="viral" post="RNA polymerase without affecting cellular synthesis of RNA or"/>
  <result pre="was developed in Japan and approved in 2014 for treating" exact="viral" post="strains unresponsive to current antivirals [54,55]. Chloroquine (ResochinÂ®, AralenÂ®)"/>
  <result pre="are antimalarial drugs. The latter drug is also used in" exact="rheumatoid arthritis" post="and lupus treatments. Both drugs possess a high level"/>
  <result pre="antimalarial drugs. The latter drug is also used in rheumatoid" exact="arthritis" post="and lupus treatments. Both drugs possess a high level"/>
  <result pre="The latter drug is also used in rheumatoid arthritis and" exact="lupus" post="treatments. Both drugs possess a high level of toxicity,"/>
  <result pre="trials. Umifenovir is name of arbidol, which is an original" exact="Russian" post="antiviral drug widely used for etiotropic therapy of influenza"/>
  <result pre="familiar both to patients and researchers. Up to now, its" exact="primary" post="therapeutic action has not yet been known for certain:"/>
  <result pre="active form that blocks RNA polymerase, an essential component of" exact="viral" post="replication. It is being studied in five Phase III"/>
  <result pre="antiviral drug, which is approved by FDA for treatment of" exact="respiratory" post="syncytial virus and hepatitis C virus infection. This drug,"/>
  <result pre="approved by FDA for treatment of respiratory syncytial virus and" exact="hepatitis C" post="virus infection. This drug, discovered in 1972, can be"/>
  <result pre="FDA for treatment of respiratory syncytial virus and hepatitis C" exact="virus infection." post="This drug, discovered in 1972, can be administered to"/>
  <result pre="found clinically effective against influenza, herpesvirus infections, hemorrhagic fever and" exact="Lassa fever" post="but ineffective against Ebola and Marburg viruses [[64], [65],"/>
  <result pre="including marshaling a cytokine response [68,69]. IngavirinÂ® is an original" exact="Russian" post="antiviral drug for the treatment and prevention of acute"/>
  <result pre="original Russian antiviral drug for the treatment and prevention of" exact="acute" post="respiratory viral infections by influenza and non-influenza with a"/>
  <result pre="Russian antiviral drug for the treatment and prevention of acute" exact="respiratory" post="viral infections by influenza and non-influenza with a unique"/>
  <result pre="antiviral drug for the treatment and prevention of acute respiratory" exact="viral" post="infections by influenza and non-influenza with a unique mechanism"/>
  <result pre="drug for the treatment and prevention of acute respiratory viral" exact="infections" post="by influenza and non-influenza with a unique mechanism of"/>
  <result pre="unique mechanism of action. This drug provides early recognition of" exact="infection" post="and the formation of the antiviral state of cells"/>
  <result pre="reproducing and spreading in the body. It is effective against" exact="type A" post="and B viruses, adenoviruses, parainfluenza viruses, respiratory syncytial viruses,"/>
  <result pre="effective against type A and B viruses, adenoviruses, parainfluenza viruses," exact="respiratory" post="syncytial viruses, coronaviruses, metapneumoviruses, enteroviruses, including Coxsackie virus and"/>
  <result pre="inexpensive semisynthetic antibiotic drug used for the treatment of several" exact="bacterial infection." post="It was discovered 1980 and approved for medical use"/>
  <result pre="[77], [78]]. Danoprevir (ITMN-191/R7227, GanovoÂ®) is one the antivirals against" exact="hepatitis C" post="virus belonging to the second-generation group so-called, direct-acting antiviral"/>
  <result pre="for the treatment of treatment-naive patients with non-cirrhotic genotype 1b" exact="chronic hepatitis C." post="It is a potent and selective noncovalent reversible NS3"/>
  <result pre="the treatment of treatment-naive patients with non-cirrhotic genotype 1b chronic" exact="hepatitis C." post="It is a potent and selective noncovalent reversible NS3"/>
  <result pre="serine protease that plays an essential role in the HCV" exact="viral" post="replication process [[79], [80], [81], [82]]. In analyzing the"/>
  <result pre="a novel virus that can mutate rapidly [83,84]. Similar to" exact="HIV/AIDS" post="treatment, which consists of the so-called â€œAIDS cocktailâ€� therapy"/>
  <result pre="principal players in the immune system, which is overactive under" exact="viral infection" post="[94,95]. In this context, it is of interest to"/>
  <result pre="players in the immune system, which is overactive under viral" exact="infection" post="[94,95]. In this context, it is of interest to"/>
  <result pre="is more likely for compounds with â‰¤10 rotatable bonds (ROTB)," exact="total" post="HBAÂ +Â HBDÂ 2. These two parameters reflect that"/>
  <result pre="properties of drugs in the intestines and permeation of the" exact="blood-brain barrier." post="TPSA values less than 140Â Ã…2 are associated with"/>
  <result pre="blocks internalization into host cells during the early phase of" exact="infection" post="(in mice). One of the most parameters of this"/>
  <result pre="selected drugs. More precisely, this nucleotide analog prodrug, which inhibits" exact="viral" post="RNA polymerase, is only administered intravenously, and compassionate use"/>
  <result pre="(8), ribavirin (9) and remdesivir (1) (TPSAÂ =Â 143.15â€&quot;203.57Â Ã…2)." exact="Increased" post="TPSA values are also observed for macrocyclic molecule drugs"/>
  <result pre="well resorbed after oral administration, and its distribution to the" exact="brain" post="is discouraged by the blood-brain-barrier (TPSAÂ &amp;gt;Â 140Â Ã…2)"/>
  <result pre="a sulfate, and both drugs are usually absorbed in the" exact="upper" post="intestinal tract [105]. Interestingly, these drugs possess molecular polar"/>
  <result pre="candidates could switch to 2-3 additional human targets. Second, as" exact="viral" post="anti-3CLpro/PLpro activities, drugs 2, 3 and 14 could also"/>
  <result pre="enzymes, and it is logical but remdesivir and favipiravir, as" exact="viral" post="RdRp inhibitors involved in viral replication inhibition, can act"/>
  <result pre="but remdesivir and favipiravir, as viral RdRp inhibitors involved in" exact="viral" post="replication inhibition, can act on human protease enzymes and"/>
  <result pre="activity. According to recent work on control of the SARS-CoV-2" exact="infection" post="inÂ vitro, hydroxychloroquine was less toxic and more efficient"/>
  <result pre="vitro, hydroxychloroquine was less toxic and more efficient as a" exact="viral" post="inhibitor than chloroquine [106], which confirms the current in"/>
  <result pre="associated with certain serious although uncommon adverse events, including cardiomyopathy," exact="bone marrow suppression" post="and hypoglycemia [108]. In addition, it was found early"/>
  <result pre="although uncommon adverse events, including cardiomyopathy, bone marrow suppression and" exact="hypoglycemia" post="[108]. In addition, it was found early on that"/>
  <result pre="embryotoxic nor fetotoxic when used at the usual dosage for" exact="malaria" post="prophylaxis [109]. The recent work of Wolfram etÂ al."/>
  <result pre="work of Wolfram etÂ al. which reports new details on" exact="viral" post="cell entry inhibition of (hydroxy) chloroquine, offers a cautiously"/>
  <result pre="remarks Reprofiling a drug or experimental agent for a concrete" exact="disease" post="is a complex task that requires time and fundamental"/>
  <result pre="and transport properties, are important drugs in the treatment of" exact="malaria" post="as well as severe rheumatoid arthritis and systemic lupus"/>
  <result pre="drugs in the treatment of malaria as well as severe" exact="rheumatoid arthritis" post="and systemic lupus erythematosus diseases in which they bind"/>
  <result pre="in the treatment of malaria as well as severe rheumatoid" exact="arthritis" post="and systemic lupus erythematosus diseases in which they bind"/>
  <result pre="treatment of malaria as well as severe rheumatoid arthritis and" exact="systemic" post="lupus erythematosus diseases in which they bind to a"/>
  <result pre="of malaria as well as severe rheumatoid arthritis and systemic" exact="lupus erythematosus" post="diseases in which they bind to a heme moiety"/>
  <result pre="contrariwise, combination therapy was associated with a significantly improved the" exact="chest" post="CT scans in 7-day [126]. Returning to the idea"/>
  <result pre="or even three pharmacophore groups that act selectively on different" exact="viral" post="replication targets (RdRp/3CLpro and RdRp/PLpro), viral cell entry (S"/>
  <result pre="act selectively on different viral replication targets (RdRp/3CLpro and RdRp/PLpro)," exact="viral" post="cell entry (S protein/ACE2) and regulation of the human"/>
  <result pre="(S protein/ACE2) and regulation of the human immune response to" exact="viral infection" post="(JAK 1/JAK 2/interleukin (IL)-1Î² and IL-6). Understanding the mechanisms"/>
  <result pre="protein/ACE2) and regulation of the human immune response to viral" exact="infection" post="(JAK 1/JAK 2/interleukin (IL)-1Î² and IL-6). Understanding the mechanisms"/>
  <result pre="fight COVID-19. However, other drugs, such as favipiravir (AviganÂ®), a" exact="viral" post="RNA polymerase inhibitor, or tilarone (AmixinÂ®), an inducer of"/>
  <result pre="[136,137], while the biological-structural and medical studies of the virus," exact="disease" post="and its symptoms have progressed [[138], [139], [140], [141],"/>
  <result pre="Actemra/RoActemraÂ®) is being studying for hospitalized patients with severe COVID-19" exact="pneumonia" post="(phase 3). Favipiravir, an inexpensive antiviral drug, was approved"/>
  <result pre="dexamethasone (glucocorticoid) reduced deaths in hospitalized patients with severe COVID-19" exact="disease" post="[144], but once again, more investigation on this drug"/>
  <result pre="declare no competing interest. References References 1GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.DrostenC.GulyaevaA.A.The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
  <result pre="no competing interest. References References 1GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.DrostenC.GulyaevaA.A.The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.52020536554"/>
  <result pre="coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.52020536554 2GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.DrostenC.GulyaevaA.A.Severe" exact="acute" post="respiratory syndrome-related coronavirus-The species and its viruses, a statement"/>
  <result pre="classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.52020536554 2GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.DrostenC.GulyaevaA.A.Severe acute" exact="respiratory" post="syndrome-related coronavirus-The species and its viruses, a statement of"/>
  <result pre="Study Group2020BioRxiv10.1101/2020.02.07.937862 3RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.Characterization of a novel coronavirus associated with severe" exact="acute" post="respiratory syndromeScience3005624200313941399 4ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from"/>
  <result pre="Group2020BioRxiv10.1101/2020.02.07.937862 3RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.Characterization of a novel coronavirus associated with severe acute" exact="respiratory" post="syndromeScience3005624200313941399 4ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a"/>
  <result pre="4ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN.Â Engl. J. Med.36719201218141820 5ChhikaraB.S.RathiB.SinghJ.PoonamF.N.U.Corona virus SARS-CoV-2"/>
  <result pre="pneumonia in Saudi ArabiaN.Â Engl. J. Med.36719201218141820 5ChhikaraB.S.RathiB.SinghJ.PoonamF.N.U.Corona virus SARS-CoV-2" exact="disease" post="COVID-19: infection, prevention and clinical advances of the prospective"/>
  <result pre="drug therapeuticsChem. Biol. Lett.7120206372 6RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ.Â Autoimmun.109202010243310.1016/j.jaut.2020.102433May 7TangB.BragazziN.L.LiQ.TangS.XiaoY.WuJ.An updated estimation of the risk"/>
  <result pre="of transmission of the novel coronavirus (2019-nCov)Infect. Dis. Model.52020248255 8WangJ.T.ChangS.C.Severe" exact="acute" post="respiratory syndromeCurr. Opin. Infect. Dis.172004143148 9Middle East respiratory syndrome"/>
  <result pre="transmission of the novel coronavirus (2019-nCov)Infect. Dis. Model.52020248255 8WangJ.T.ChangS.C.Severe acute" exact="respiratory" post="syndromeCurr. Opin. Infect. Dis.172004143148 9Middle East respiratory syndrome coronavirus"/>
  <result pre="Model.52020248255 8WangJ.T.ChangS.C.Severe acute respiratory syndromeCurr. Opin. Infect. Dis.172004143148 9Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)Available at:https://www.who.int/emergencies/mers-cov/en/ 10Coronavirus disease (COVID-19) advice for"/>
  <result pre="8WangJ.T.ChangS.C.Severe acute respiratory syndromeCurr. Opin. Infect. Dis.172004143148 9Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)Available at:https://www.who.int/emergencies/mers-cov/en/ 10Coronavirus disease (COVID-19) advice for the"/>
  <result pre="Infect. Dis.172004143148 9Middle East respiratory syndrome coronavirus (MERS-CoV)Available at:https://www.who.int/emergencies/mers-cov/en/ 10Coronavirus" exact="disease" post="(COVID-19) advice for the publicAvailable at:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public 11MenacheryV.YountB.L.Jr.DebbinkK.AgnihothramS.GralinskiL.E.PlanteJ.A.AÂ SARS-like cluster"/>
  <result pre="and MERS: recent insights into emerging coronavirusesNat. Rev. Microbiol.148201652353427344959 13ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.AÂ" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="a new coronavirus of probable bat originNature5797798202027027332015507 14Wuhan Seafood Market" exact="Pneumonia" post="Virus Isolate Wuhan-Hu-1, Complete Genome. Nucleotide, National Center for"/>
  <result pre="probable bat originNature5797798202027027332015507 14Wuhan Seafood Market Pneumonia Virus Isolate Wuhan-Hu-1," exact="Complete" post="Genome. Nucleotide, National Center for Biotechnology Information (NCBI)2009National Library"/>
  <result pre="Pharm. Anal.102202010210832282863 27ContiP.RonconiG.CaraffaA.GallengaC.E.RossR.FrydasI.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by COVID-19: anti-inflammatory strategiesJ.Â Biol. Regul. Homeost. Agents342202010.23812/conti-e 28KhanS.SiddiqueR.ShereenM.A.AliA.LiuJ.BaiQ.The"/>
  <result pre="Clin. Microbiol.585202010.1128/JCM.00187-20 29VellingiriB.JayaramayyaK.IyerM.NarayanasamyA.GovindasamyV.GiridharanB.COVID-19: a promising cure for the global panicSci." exact="Total" post="Environ.72510202013827710.1016/j.scitotenv.2020.138277July 30AronsonJ.K.FernerR.E.DeVitoN.HeneghanC.COVID-19 Trials Registered up to 8 March 2020-an"/>
  <result pre="3277â€&quot;3286. 32SmithM.SmithJ.C.Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2" exact="Viral" post="Spike Protein and Viral Spike Protein-Human ACE2 Interface2020ChemRxiv10.26434/chemrxiv.11871402.v3 33ul"/>
  <result pre="Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike" exact="Protein" post="and Viral Spike Protein-Human ACE2 Interface2020ChemRxiv10.26434/chemrxiv.11871402.v3 33ul QamarM.T.AlqahtaniS.M.AlamriM.A.ChenL.L.Structural basis"/>
  <result pre="COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and" exact="Viral" post="Spike Protein-Human ACE2 Interface2020ChemRxiv10.26434/chemrxiv.11871402.v3 33ul QamarM.T.AlqahtaniS.M.AlamriM.A.ChenL.L.Structural basis of SARS-CoV-2"/>
  <result pre="methodsActa Pharm. Sin. B105202076678832292689 43MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob. Agents Chemother.6452020http://aac.asm.org/content/64/5/e00399-20.abstract 44EkinsS.MottinM.RamosP.R.SousaB.K.NevesB.J.FoilD.H.DÃ©jÃ vu: stimulating open drug"/>
  <result pre="Clin. Risk Manag.45200810231033 53CroxtallJ.D.M PerryC.Lopinavir/ritonavir, Drugs701420101885191520836579 54FurutaY.GowenB.B.TakahashiK.ShirakiK.SmeeD.F.BarnardD.L.Favipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitorAntivir. Res.1002201344645424084488 55FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad-spectrum inhibitor"/>
  <result pre="RNA polymerase inhibitorAntivir. Res.1002201344645424084488 55FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad-spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Japan Acad., Series B9372017449463 56PiscianzE.CuzzoniE.SharmaR.TesserA.SapraP.TommasiniA.Reappraisal of antimalarials"/>
  <result pre="a quarter-century after. Past, present and future of the original" exact="Russian" post="antiviralRuss. Chem. Rev.8762018509552 61BlaisingJ.PolyakS.J.PÃ©cheurE.I.Arbidol as a broad-spectrum antiviral: an"/>
  <result pre="action of ribavirin against distinct virusesRev. Med. Virol.1612006374816287208 65Loustaud-RattiV.RousseauA.MarquetP.DenisF.AlainS.Ribavirin in" exact="chronic hepatitis" post="C: past and futureExpert Rev. Anti-infect. Ther.73200924925319344238 66XiaY.QuF.PengL.Triazole nucleoside"/>
  <result pre="of ribavirin against distinct virusesRev. Med. Virol.1612006374816287208 65Loustaud-RattiV.RousseauA.MarquetP.DenisF.AlainS.Ribavirin in chronic" exact="hepatitis" post="C: past and futureExpert Rev. Anti-infect. Ther.73200924925319344238 66XiaY.QuF.PengL.Triazole nucleoside"/>
  <result pre="74TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09" exact="virus infection" post="by interfering with virus internalization processJ.Â Antibiot.7210201975976831300721 75OheM.ShidaH.JodoS.KusunokiY.SekiM.FuruyaK.GoudarziH.Macrolide treatment"/>
  <result pre="a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus" exact="infection" post="by interfering with virus internalization processJ.Â Antibiot.7210201975976831300721 75OheM.ShidaH.JodoS.KusunokiY.SekiM.FuruyaK.GoudarziH.Macrolide treatment"/>
  <result pre="replication of SARS-CoV-2 inÂ vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.1047 79SeiwertS.D.AndrewsS.W.JiangY.SerebryanyV.TanH.KossenK.Preclinical characteristics of the" exact="hepatitis C" post="virus NS3/4A protease inhibitor ITMN-191 (R7227)Antimicrob. Agents Chemother.521220084432444118824605 80JiangY.AndrewsS.W.CondroskiK.R.BuckmanB.SerebryanyV.WenglowskyS.Discovery"/>
  <result pre="of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of" exact="hepatitis C" post="virus (HCV) NS3/4A proteasJ.Â Med. Chem.57520141753176923672640 81MarkhamA.KeamS.J.Danoprevir: first global"/>
  <result pre="Autoimmun.109202010243410.1016/j.jaut.2020.102434 84GrubaughN.D.PetroneM.E.C HolmesE.We shouldnâ€™t worry when a virus mutates during" exact="disease" post="outbreaksNat. Microbiol.54202052953032071422 85collab: Antiretroviral Therapy Cohort CollaborationLife expectancy of"/>
  <result pre="transport across the human erythrocyte membraneBiochem. Pharmacol.411199123301986742 100CaoY.C.DengQ.X.DaiS.X.Remdesivir for severe" exact="acute" post="respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of"/>
  <result pre="across the human erythrocyte membraneBiochem. Pharmacol.411199123301986742 100CaoY.C.DengQ.X.DaiS.X.Remdesivir for severe acute" exact="respiratory" post="syndrome coronavirus 2 causing COVID-19: an evaluation of the"/>
  <result pre="the human erythrocyte membraneBiochem. Pharmacol.411199123301986742 100CaoY.C.DengQ.X.DaiS.X.Remdesivir for severe acute respiratory" exact="syndrome" post="coronavirus 2 causing COVID-19: an evaluation of the evidenceTrav."/>
  <result pre="patients with severe covid-19N.Â Engl. J. Med.38220202327233632275812 102ChaccourC.HammannF.RabinovichN.R.Ivermectin to reduce" exact="malaria" post="transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and"/>
  <result pre="pharmacodynamic considerations regarding efficacy and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and Chloroquine" exact="Retinopathy" post="in: Hydroxychloroquine and Chloroquine Retinopathy2014Springer Science+Business Media New York3563"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="inÂ vitroCell Discov6120201610.1038/s41421-020-0156-032194981 107MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for chloroquine and"/>
  <result pre="is not associated with improved outcomes in patients with coronavirus" exact="disease" post="2019: a retrospective studyClin. Microbiol. Infect.267202091792132344167 113KadamR.U.WilsonI.A.Structural basis of"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV2)Clin. Infect. Dis.202010.1093/cid/ciaa237ciaa237 117ChaccourC.HammannF.RamÃ³n-GarcÃ­aS.RabinovichN.R.Ivermectin and"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV2)Clin. Infect. Dis.202010.1093/cid/ciaa237ciaa237 117ChaccourC.HammannF.RamÃ³n-GarcÃ­aS.RabinovichN.R.Ivermectin and novel"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV2)Clin. Infect. Dis.202010.1093/cid/ciaa237ciaa237 117ChaccourC.HammannF.RamÃ³n-GarcÃ­aS.RabinovichN.R.Ivermectin and novel coronavirus"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV2)Clin. Infect. Dis.202010.1093/cid/ciaa237ciaa237 117ChaccourC.HammannF.RamÃ³n-GarcÃ­aS.RabinovichN.R.Ivermectin and novel coronavirus" exact="disease" post="(COVID-19): keeping rigor in times of urgencyAm. J. Trop."/>
  <result pre="chemoprophylaxis and/or treatment?J.Â Am. Acad. Dermatol.202010.1016/j.jaad.2020.04.017 123YuJ.WangM.ZhouK.ZhangS.XiangB.Clinical characteristics of Coronavirus" exact="Disease" post="2019 in Hangzhou, China: the combination of lopinavir/ritonavir, interferon,"/>
  <result pre="Infect.8112020e21e2332283143 126DengL.LiC.ZengQ.LiuX.LiX.ZhangH.Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: a retrospective cohort studyJ.Â Infect.8112020e1e5 127ScavoneC.BruscoS.BertiniM.SportielloL.RafanielloC.ZoccoliA.Current pharmacological treatments"/>
  <result pre="126DengL.LiC.ZengQ.LiuX.LiX.ZhangH.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: a retrospective cohort studyJ.Â Infect.8112020e1e5 127ScavoneC.BruscoS.BertiniM.SportielloL.RafanielloC.ZoccoliA.Current pharmacological treatments"/>
 </snippets>
</snippetsTree>
